Today: 16 March 2026
Denison Mines Stock Price Falls 6% as Phoenix Uranium Mine Enters a Critical Build Phase
16 March 2026
2 mins read

Denison Mines Stock Price Falls 6% as Phoenix Uranium Mine Enters a Critical Build Phase

TORONTO, March 16, 2026, 12:55 EDT

Denison Mines Corp.’s U.S.-listed stock slid 6.3% to $3.58 as of 12:39 p.m. EDT, despite a lift in both Wall Street and Toronto equities on softer oil. The shares kicked off at $3.84, with volume topping 19 million at that point. Reuters

The decline stings for a company eager to shed its image as just a uranium developer. Denison still plans to kick off site prep and construction at its Phoenix project in Saskatchewan this March, aiming for first output in mid-2028. That timeline would put Phoenix among the rare, significant new uranium plays expected before decade’s end. Denison Mines Corp.

The timing is key here: uranium supply’s grown tighter lately. Back in January, Reuters flagged U.S. uranium consumption outpacing what’s coming out of domestic mines, with long-term contracts approaching $100 a pound. Denison just added last week that uranium market negotiations have been driving those long-term prices even higher. Reuters

Denison posted its 2025 results last week, sticking with its final investment decision for the Phoenix project. CEO David Cates said Denison is “ready to commence site preparation” before the month is out, citing completed approvals, procurement, engineering, and financing. Denison Mines Corp.

The federal go-ahead landed in February, when the Canadian Nuclear Safety Commission signed off on both the environmental assessment and the construction licence for Wheeler River. Cates described it as a “landmark achievement.” According to the company, Phoenix now stands as Canada’s first uranium project to secure approval for in-situ recovery (ISR)—a process that injects solution into ore, dissolves the uranium, then pumps it up to the surface—and also marks the first major uranium development in the country to get construction clearance in over two decades. Denison Mines Corp.

Denison maintains it has the resources to get the project off the ground, despite the hefty price tag. Back in January, the company pegged post-FID initial capital for Phoenix at roughly C$600 million—about 20% higher than the 2023 feasibility study after factoring in inflation. As of September 30, Denison reported more than C$700 million in cash, physical uranium, and investments. The company also flagged its US$345 million convertible note deal from August, saying that supports development spending. Denison Mines Corp.

The drop on Monday outpaced declines seen in a few rivals. NexGen Energy, which trades in the U.S., slipped 4.2%. Cameco managed a slight 0.2% gain. Traders, it seems, weren’t pulling out of uranium stocks across the board.

LSEG figures cited by Reuters put Denison’s 2025 revenue at $4.9 million, with a net loss hitting $217.3 million. That’s left shares tethered closely to how Phoenix performs and whether uranium prices stay elevated during the buildout. Reuters

The road ahead looks tougher. In January, Denison raised its Phoenix project cost estimate, citing inflation and tweaks to the plan. The company also flagged that once construction gets underway, real-world conditions could push costs and timelines away from current technical studies and forecasts. Denison Mines Corp.

With permits in hand, investors have shifted focus to mobilization. According to the company, most contract awards wrapped up in January. That puts the spotlight on Denison stock: can the roughly two-year build-out actually stay on track and hit the mid-2028 production goal? Denison Mines Corp.

Stock Market Today

  • ImmunityBio Shares Surge 7% Following Breakthrough in NK Cell Therapy Manufacturing
    March 16, 2026, 3:11 PM EDT. Shares of ImmunityBio (IBRX) jumped over 7% on Friday after completing two key manufacturing programs for its memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform. The NK2022 and NK2023 programs validated a scalable, safe process to collect and convert immune cells into NK therapies. The firm demonstrated successful apheresis collection from 64 subjects without serious adverse events, enabling up to 5 billion NK cells per collection, enough for multiple treatment doses. ImmunityBio administered 23 doses to cancer patients, showing repeat dosing and cryo-banking feasibility. Year to date, IBRX stock has soared 300%, outperforming the biotech sector. The company also completed a phase I safety study combining M-ceNK cells with Anktiva in refractory solid tumor patients, confirming safety. ImmunityBio holds a Zacks Rank #3 (Hold).
Dow Jones Today: Index Rises 300 Points as Oil Retreats Before Fed
Previous Story

Dow Jones Today: Index Rises 300 Points as Oil Retreats Before Fed

Go toTop